This week, the Hang Seng Index fell 0.52% to 19898.77.

The Hong Kong stock IPO market is relatively deserted this week, with a total of three new shares on the table, one new stock listing and one new share offering. Among them$KE Holdings Inc.-W (02423.HK) $It officially landed on the Hong Kong Stock Exchange on May 11 and became the first back-to-Hong Kong Chinese-listed stock to be dual-listed in Hong Kong by "introduction".

It is reported that$NIO Inc. (NIO.US) $$NIO Inc.-SW (09866.HK) $According to a recent announcement, its Class A common shares are expected to be listed on the main board of the Singapore Exchange on May 20 (Singapore time). Earlier, NIO Inc. announced that he had received a listing qualification letter from the SGX on the proposed secondary listing of its shares on the main board of the SGX.

According to public data, Byte Jump (Hong Kong) Co., Ltd. changed its name to Douyin Group (Hong Kong) Co., Ltd. on May 7, market analysis believes that this may be byte jump's intention to list in Hong Kong with Douyin as the main body of business. A person in charge of Douyin declined to comment.

This week, a total of 3 new shares delivery table.

Starry ChineseIs the market leader in China's entertainment-related IP industry. According to the Frost Sullivan report, the company is the largest IP creator and operator in China by 2020 revenue, with a market share of 2 per cent. In 2012, the company launched The Voice of China, one of China's most popular singing competition programs.

Ten seasons later, The Voice of China has set a record for the longest variety show in China, according to Frost Sullivan. The company has also created and operated other long-time popular variety shows IP (such as "masked singers will guess", "good Chinese songs" and "brilliant Chinese").

Boan biologyFounded in December 2013, registered in Yantai High-tech Zone, is$Green Leaf Pharmaceutical (02186.HK) $It specializes in the development of therapeutic antibodies, focusing on oncology, autoimmune diseases, pain and endocrine diseases.

At present, Boan Biology has built more than 10 innovative antibodies with international intellectual property protection and 8 product combinations of biological similar drugs, among which the anti-tumor biological drug Boyonol (bevacizumab injection) has been approved by the State Drug Administration to be marketed. it is the first product to be approved and listed in the research product pipeline.

Jintaifeng InternationalBased in Guangdong Province, China, mainly engaged in wholesale oil products and other petrochemical products. The oil products bought and sold can be roughly divided into refined oil, fuel oil and other petrochemical products. All the products of the Group are sold in China, mainly in Guangdong Province. In the three years ended December 31, 2021, sales to Chinese state-owned enterprises accounted for 58.2%, 45.3% and 57.0% of the total revenue, respectively, while purchases from Chinese state-owned enterprises accounted for 69.5%, 28.2% and 6.2% of the total purchases, respectively.

This week only$Yunkang Group (02325.HK) $The IPO is currently closed for subscription. By the end of the IPO, Yunkang Group has a margin multiple of 1.33 times and a financing subscription of HK $145 million, which will be officially listed on May 18.

Only one new stock went public this week.

Integrated real estate transaction and service platform$KE Holdings Inc.-W (02423.HK) $It officially landed on the Hong Kong Stock Exchange on May 11 and became the first back-to-Hong Kong Chinese-listed stock to be dual-listed in Hong Kong by "introduction". The shares are traded in the units of 10 Class A common shares each. As of May 13, KE Holdings Inc.-W closed at HK $31.75, up 2.57 per cent for the week.